Is Now The Time To Put Grown Rogue International (CSE:GRIN) On Your Watchlist?
Feb 10
Have your own idea? Try our Stock Screener
Canadian (TSX) Pharma Industry Analysis
UpdatedFeb 14, 2025
DataAggregated Company Financials
Companies69
- 7D-3.7%
- 3M-18.2%
- 1Y-45.6%
- YTDn/a
Over the last 7 days, the Pharma industry has dropped 5.9%, driven by Curaleaf Holdings declining 11%. In contrast, Aurora Cannabis has gained 18%. However, the industry is down 44% over the past year. As for the next few years, earnings are expected to grow by 56% per annum.
Industry Valuation and Performance
Has the Canadian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 14 Feb 2025 | CA$12.4b | CA$12.1b | -CA$2,212,969,547.00 | 23.8x | -5.6x | 1x |
| Sun, 12 Jan 2025 | CA$12.4b | CA$12.2b | -CA$2,417,209,526.77 | 28.7x | -5.1x | 1x |
| Tue, 10 Dec 2024 | CA$13.6b | CA$12.0b | -CA$2,581,746,931.12 | 23x | -5.3x | 1.1x |
| Thu, 07 Nov 2024 | CA$19.1b | CA$11.9b | -CA$2,771,044,784.66 | 18x | -6.9x | 1.6x |
| Sat, 05 Oct 2024 | CA$18.6b | CA$11.6b | -CA$2,680,134,100.30 | 27.4x | -6.9x | 1.6x |
| Mon, 02 Sep 2024 | CA$17.1b | CA$11.6b | -CA$2,690,218,404.94 | 20.2x | -6.4x | 1.5x |
| Wed, 31 Jul 2024 | CA$20.1b | CA$11.8b | -CA$3,212,184,320.34 | 20x | -6.2x | 1.7x |
| Fri, 28 Jun 2024 | CA$20.4b | CA$11.8b | -CA$3,239,151,617.43 | 18.8x | -6.3x | 1.7x |
| Sun, 26 May 2024 | CA$21.8b | CA$11.9b | -CA$3,490,501,699.08 | 12.8x | -6.2x | 1.8x |
| Tue, 23 Apr 2024 | CA$23.2b | CA$12.0b | -CA$3,476,028,729.95 | 8.2x | -6.7x | 1.9x |
| Thu, 21 Mar 2024 | CA$22.6b | CA$11.8b | -CA$3,477,097,457.18 | 9.5x | -6.5x | 1.9x |
| Sat, 17 Feb 2024 | CA$22.3b | CA$12.0b | -CA$4,643,332,391.61 | 10.4x | -4.8x | 1.9x |
| Mon, 15 Jan 2024 | CA$20.3b | CA$12.3b | -CA$6,744,251,485.00 | 9.3x | -3x | 1.7x |
| Wed, 13 Dec 2023 | CA$17.3b | CA$12.4b | -CA$6,782,848,879.00 | 8.2x | -2.6x | 1.4x |
| Fri, 10 Nov 2023 | CA$16.9b | CA$12.5b | -CA$7,314,992,422.00 | 10.3x | -2.3x | 1.4x |
| Sun, 08 Oct 2023 | CA$18.6b | CA$12.4b | -CA$7,334,632,248.00 | 15x | -2.5x | 1.5x |
| Tue, 05 Sep 2023 | CA$18.0b | CA$13.0b | -CA$7,911,625,052.00 | 13.3x | -2.3x | 1.4x |
| Thu, 03 Aug 2023 | CA$15.2b | CA$13.3b | -CA$9,743,091,053.00 | 12.1x | -1.6x | 1.1x |
| Sat, 01 Jul 2023 | CA$14.8b | CA$13.2b | -CA$9,514,993,365.00 | 11.4x | -1.6x | 1.1x |
| Mon, 29 May 2023 | CA$14.9b | CA$13.4b | -CA$10,471,665,836.00 | 10.2x | -1.4x | 1.1x |
| Wed, 26 Apr 2023 | CA$14.9b | CA$13.5b | -CA$9,997,376,351.00 | 10.8x | -1.5x | 1.1x |
| Fri, 24 Mar 2023 | CA$17.2b | CA$13.8b | -CA$10,095,082,425.00 | 9.1x | -1.7x | 1.2x |
| Sun, 19 Feb 2023 | CA$20.4b | CA$13.6b | -CA$10,307,884,782.00 | 10.5x | -2x | 1.5x |
| Tue, 17 Jan 2023 | CA$20.9b | CA$13.5b | -CA$10,099,014,878.00 | 13.4x | -2.1x | 1.5x |
| Thu, 15 Dec 2022 | CA$23.4b | CA$13.6b | -CA$10,200,923,205.00 | 15.9x | -2.3x | 1.7x |
| Sat, 12 Nov 2022 | CA$29.7b | CA$13.3b | -CA$9,951,468,821.00 | 13.6x | -3x | 2.2x |
| Mon, 10 Oct 2022 | CA$30.4b | CA$13.4b | -CA$9,400,489,803.00 | 12.5x | -3.2x | 2.3x |
| Wed, 07 Sep 2022 | CA$30.9b | CA$13.1b | -CA$8,794,047,387.00 | 15x | -3.5x | 2.4x |
| Fri, 05 Aug 2022 | CA$27.9b | CA$12.3b | -CA$5,845,497,689.00 | 13.4x | -4.8x | 2.3x |
| Sun, 03 Jul 2022 | CA$25.0b | CA$12.2b | -CA$5,766,408,417.00 | 11.5x | -4.3x | 2x |
| Tue, 31 May 2022 | CA$31.2b | CA$12.1b | -CA$5,493,611,920.00 | 9.7x | -5.7x | 2.6x |
| Thu, 28 Apr 2022 | CA$35.8b | CA$11.9b | -CA$4,992,110,593.00 | 10.5x | -7.2x | 3x |
| Sat, 26 Mar 2022 | CA$44.7b | CA$11.4b | -CA$4,539,815,523.00 | 15x | -9.9x | 3.9x |
| Mon, 21 Feb 2022 | CA$50.4b | CA$10.9b | -CA$4,170,773,176.00 | 13.8x | -12.1x | 4.6x |
Price to Earnings Ratio
-12.1x
Current Industry PE
- Investors are pessimistic on the Canadian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 1.8x is higher than the industry's current PS ratio of 1.0x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
- Revenues for these companies have grown 3.5% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Canadian Pharma compare with similar industries?
| CA Market | 0.37% | |
| Healthcare | -1.55% | |
| Pharma | -3.72% | |
| Pharma | -3.72% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| GTII Green Thumb Industries | CA$10.35 | 2.0% +CA$47.2m | -44.4% | PE27x | |
| VREO Vireo Growth | CA$0.75 | 15.4% +CA$36.6m | 36.4% | PS2x | |
| ACB Aurora Cannabis | CA$9.40 | 4.9% +CA$24.1m | 80.8% | PE29x | |
| GRIN Grown Rogue International | CA$0.87 | 6.1% +CA$11.1m | 35.9% | PE35.3x | |
| NGEN NervGen Pharma | CA$3.00 | 4.9% +CA$9.8m | -12.5% | PB23x |